Library Subscription: Guest
Journal of Environmental Pathology, Toxicology and Oncology

Published 4 issues per year

ISSN Print: 0731-8898

ISSN Online: 2162-6537

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.4 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.8 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.5 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00049 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.59 SJR: 0.429 SNIP: 0.507 CiteScore™:: 3.9 H-Index: 49

Indexed in

Role of Cannabinoid and Vanilloid Receptors in Invasion of Human Breast Carcinoma Cells

Volume 31, Issue 4, 2012, pp. 377-387
DOI: 10.1615/JEnvironPatholToxicolOncol.2013005859
Get accessGet access

ABSTRACT

It is known that the diversified effects of cannabinoid on the fate of carcinoma cells are mediated predominantly through receptors. However, little is known about the effects of the individual activities of cannabinoid and noncannabinoid receptors. Here we investigate the role of cannabinoid receptor (CB) 1, CB2, and transient receptor potential vanilloid type 1 in cell proliferation and invasion patterns in the MDA-MB-231 cell line.
Our results showed that activation of CB1 and vanilloid receptors by methanandamide, a nonselective agonist, and arachidonyl-2'-choloroethylamide (ACEA) and N-oleoyldopamine, selective agonists, reduced invasion of MDA-MB-231 cells at pharmacological concentrations. Accordingly, CB1 activation resulted in decreased expression of matrix metalloproteinase (MMP) 2. On the other hand, administration of a CB2 agonist (CB65) increased cell invasion and expression of MMP2. The data obtained from MTT assay did not show any correlation between reduced invasion and cytotoxic effects of drugs. In addition, the level of vascular endothelial growth factor was significantly reduced in treatment with (R)-(+)-methanandamide, ACEA, CB65, and AM251 (a potent agonist for GPR55 and selective antagonist of CB1) compared with control. Elevated expression of cyclooxygenase-2 was observed in all of the MDA-MB-231 cells treated with agonists.
These results underline the influence of cannabinoid and vanilloid receptors on the invasiveness of MDA-MB-231 human breast carcinoma cells.

CITED BY
  1. Ramer Robert, Hinz Burkhard, , 314, 2015. Crossref

  2. dos Santos Daiane S., Piovesan Luciana A., D’Oca Caroline R. Montes, Hack Carolina R. Lopes, Treptow Tamara G.M., Rodrigues Marieli O., Vendramini-Costa Débora B., Ruiz Ana Lucia T.G., de Carvalho João Ernesto, D’Oca Marcelo G. Montes, Antiproliferative activity of synthetic fatty acid amides from renewable resources, Bioorganic & Medicinal Chemistry, 23, 2, 2015. Crossref

  3. Ayakannu Thangesweran, Taylor Anthony H., Willets Jonathan M., Konje Justin C., The evolving role of the endocannabinoid system in gynaecological cancer, Human Reproduction Update, 21, 4, 2015. Crossref

  4. Javid Farideh A., Phillips Roger M., Afshinjavid S., Verde Roberta, Ligresti Alessia, Cannabinoid pharmacology in cancer research: A new hope for cancer patients?, European Journal of Pharmacology, 775, 2016. Crossref

  5. Ramer Robert, Hinz Burkhard, Antitumorigenic targets of cannabinoids – current status and implications, Expert Opinion on Therapeutic Targets, 20, 10, 2016. Crossref

  6. Ramer Robert, Hinz Burkhard, Cannabinoids as Anticancer Drugs, in Cannabinoid Pharmacology, 80, 2017. Crossref

  7. Freund Patricia, Porpaczy Edit A., Le Trang, Gruber Michaela, Pausz Clemens, Staber Philipp, Jäger Ulrich, Vanura Katrina, Velasco Guillermo, Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation, PLOS ONE, 11, 6, 2016. Crossref

  8. Mir Manzoor A., Hamdani Syed S., Sheikh Bashir A., Mehraj Umar, Recent Advances in Metabolites from Medicinal Plants in Cancer Prevention and Treatment, Current Immunology Reviews, 15, 2, 2019. Crossref

  9. Chakravarti Bandana, Ravi Janani, Ganju Ramesh K., Cannabinoids as therapeutic agents in cancer: current status and future implications, Oncotarget, 5, 15, 2014. Crossref

  10. He Dan, Wang Jun, Zhang Chunfang, Shan Bin, Deng Xiyun, Li Bin, Zhou Yanwu, Chen Wei, Hong Jidong, Gao Yang, Chen Zhuchu, Duan Chaojun, Down-regulation of miR-675-5p contributes to tumor progression and development by targeting pro-tumorigenic GPR55 in non-small cell lung cancer, Molecular Cancer, 14, 1, 2015. Crossref

  11. Susanna Tojkander Sari, TRPV Family Ion Channels in the Mammary Epithelium: Role in Normal Tissue Homeostasis and along Breast Cancer Progression, in Ion Channels - From Basic Properties to Medical Treatment [Working Title], 2022. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain